A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine



Fleeman, Nigel ORCID: 0000-0002-4637-9779, Houten, Rachel ORCID: 0000-0002-4315-7732, Chaplin, Marty ORCID: 0000-0002-7097-8704, Beale, Sophie ORCID: 0000-0003-0164-103X, Boland, Angela, Dundar, Yenal, Greenhalgh, Janette ORCID: 0000-0003-4812-1904, Duarte, Rui and Shenoy, Aditya
(2019) A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19 (1).

[img] Text
Fleeman et al BMC Cancer 2019.pdf - OA Published Version

Download (1MB) | Preview
Item Type: Article
Uncontrolled Keywords: Thyroid cancer, Systematic review, Clinical effectiveness, Lenvatinib, Sorafenib, Tyrosine kinase inhibitor
Depositing User: Symplectic Admin
Date Deposited: 19 Dec 2019 15:58
Last Modified: 25 Jan 2022 19:29
DOI: 10.1186/s12885-019-6369-7
Open Access URL: http://v/
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3067070